Advertisement

Update on Management of Coats’ Disease

  • Janelle Fassbender Adeniran
  • Oluwasayo Akinyosoye
  • Aparna RamasubramanianEmail author
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

Coats’ disease is an exudative vasculopathy that usually develops in children. The conventional treatment is laser photocoagulation and cryotherapy. Use of anti-VEGF agents is controversial and future studies are required to determine its role in the management of exudation and edema from Coats’ disease.

Keywords

Coats’ disease Leukocoria Retinal detachment Exudation Retinoblastoma 

Notes

Conflict of Interest

None.

Funding Sources

This work was supported in part by an unrestricted institutional grant from Research to Prevent Blindness, NY, NY.

References

  1. 1.
    Shields JA, Shields CL. Review: Coats’ disease: the 2001 LuEsther T. Mertz lecture. Retina. 2002;22(1):80–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Ghorbanian S, Jaulim A, Chatziralli IP. Diagnosis and treatment of Coats’ disease: a review of the literature. Ophthalmologica. 2012;227(4):175–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Rishi E, et al. Coats’ disease of adult-onset in 48 eyes. Indian J Ophthalmol. 2016;64(7):518–23.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Sigler EJ, et al. Current management of Coats’ disease. Surv Ophthalmol. 2014;59(1):30–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Saatci AO, Doruk HC, Yaman A. Intravitreal dexamethasone implant (Ozurdex) in Coats’ disease. Case Rep Ophthalmol. 2013;4(3):122–8.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Ghazi NG, et al. Intravitreal triamcinolone in Coats’ disease. Ophthalmology. 2012;119(3):648–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Chaudhary KM, Mititelu M, Lieberman RM. An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats’ disease, best disease, and uveitis with childhood neovascularization. J Pediatr Ophthalmol Strabismus. 2013;50(1):11–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Kaul S, et al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol. 2010;58(1):76–8.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Cakir M, Cekic O, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats’ disease. J AAPOS. 2008;12(3):309–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Eagle RC Jr. Eye pathology. Philadelphia: Lippincott & Williams; 2011. p. 221–2.Google Scholar
  11. 11.
    Shields JA, et al. Classification and management of Coats’ disease: the 2000 proctor lecture. Am J Ophthalmol. 2001;131(5):572–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Bindoff LA, et al. Severe facioscapulohumeral muscular dystrophy presenting with Coats’ disease and mental retardation. Neuromuscul Disord. 2006;16(9–10):559–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Beby F, et al. Coats’ disease and bilateral cataract in a child with turner syndrome: a case report. Graefes Arch Clin Exp Ophthalmol. 2005;243(12):1291–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Schuman JS, et al. Senior-Loken syndrome (familial renal-retinal dystrophy) and Coats’ disease. Am J Ophthalmol. 1985;100(6):822–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Mansukhani S, et al. Cerebroretinal microangiopathy with calcifications and cysts (CRMCC) or “Coats’ plus”: when peripheral retinal vasculature signals neurologic disease. J AAPOS. 2017;21(5):420–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Kumar V, Chandra P, Kumar A. Ultra-wide field imaging in the diagnosis and management of adult-onset Coats’ disease. Clin Exp Optom. 2017;100(1):79–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Grosso A, et al. Pearls and pitfalls in diagnosis and management of Coats’ disease. Retina. 2015;35(4):614–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Sigler EJ, Calzada JI. Retinal angiomatous proliferation with chorioretinal anastomosis in childhood Coats’ disease: a reappraisal of macular fibrosis using multimodal imaging. Retina. 2015;35(3):537–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Rabiolo A, et al. Refining Coats’ disease by ultra-wide-field imaging and optical coherence tomography angiography. Graefes Arch Clin Exp Ophthalmol. 2017;255(10):1881–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Kumar P, Kumar V. Vitrectomy for epiretinal membrane in adult-onset Coats’ disease. Indian J Ophthalmol. 2017;65(10):1046–8.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Rishi P, et al. Coats’ disease: an Indian perspective. Indian J Ophthalmol. 2010;58(2):119–24.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Beselga D, et al. Refractory Coats’ disease of adult onset. Case Rep Ophthalmol. 2012;3(1):118–22.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Jarin RR, Teoh SC, Lim TH. Resolution of severe macular oedema in adult Coats’ syndrome with high-dose intravitreal triamcinolone acetonide. Eye (Lond). 2006;20(2):163–5.CrossRefGoogle Scholar
  24. 24.
    London NJS, Shields CL, Haller JA. Chapter 56—Coats disease. In: Ryan SJ, Sadda SVR, Hinton DR, Schachat AP, Sadda SVR, Wilkinson CP, Wiedemann P, Schachat AP, editors. Retina. 5th ed. Philadelphia: W.B. Saunders; 2013. p. 1058–70. ISBN: 9781455707379.  https://doi.org/10.1016/B978-1-4557-0737-9.00056-4.CrossRefGoogle Scholar
  25. 25.
    Shields JA, Shields CL. Differentiation of Coats’ disease and retinoblastoma. J Pediatr Ophthalmol Strabismus. 2001;38(5):262–6. quiz 302–3.PubMedGoogle Scholar
  26. 26.
    Nucci P, et al. Selective photocoagulation in Coats’ disease: ten-year follow-up. Eur J Ophthalmol. 2002;12(6):501–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Shapiro MJ, et al. Effects of green diode laser in the treatment of pediatric Coats’ disease. Am J Ophthalmol. 2011;151(4):725–731 e2.PubMedCrossRefGoogle Scholar
  28. 28.
    Cai X, et al. Treatment of stage 3 Coats’ disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach. Graefes Arch Clin Exp Ophthalmol. 2015;253(7):999–1004.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Suesskind D, et al. Pars plana vitrectomy for treatment of advanced Coats’ disease—presentation of a modified surgical technique and long-term follow-up. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):873–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in Coats’ disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2010;94(5):606–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats’ disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol. 2007;245(9):1387–8.PubMedCrossRefGoogle Scholar
  32. 32.
    He YG, et al. Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1519–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Zheng XX, Jiang YR. The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):35–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Villegas VM, et al. Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin Ophthalmol. 2014;8:973–6.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Gaillard MC, et al. Ranibizumab in the management of advanced Coats’ disease stages 3B and 4: long-term outcomes. Retina. 2014;34(11):2275–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Yang Q, et al. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats’ disease. Acta Ophthalmol. 2016;94(4):401–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Guixeres Esteve MC, Pardo Saiz AO. Coats’ disease with macular oedema responsive to aflibercept and argon laser. Arch Soc Esp Oftalmol. 2017;92(7):330–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Kase S, et al. Expression of vascular endothelial growth factor in eyes with Coats’ disease. Invest Ophthalmol Vis Sci. 2013;54(1):57–62.PubMedCrossRefGoogle Scholar
  39. 39.
    Ramasubramanian A, Shields CL. Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2012;96(3):356–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Daruich A, et al. Extramacular fibrosis in Coats’ disease. Retina. 2016;36(10):2022–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Sein J, et al. Treatment of Coats’ disease with combination therapy of Intravitreal Bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):443–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Al-Qahtani AA, Almasaud JM, Ghazi NG. Clinical characteristics and treatment outcomes of Coats’ disease in a Saudi Arabian population. Retina. 2015;35(10):2091–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Janelle Fassbender Adeniran
    • 1
  • Oluwasayo Akinyosoye
    • 1
  • Aparna Ramasubramanian
    • 1
    Email author
  1. 1.Department of Ophthalmology and Visual SciencesUniversity of LouisvilleLouisvilleUSA

Personalised recommendations